Methods and compositions for inducing complement destruction of

Details Methods and compositions for inducing complement destruction of Methods and compositions for inducing complement destruction of

1996-11-13

1999-02-09

Feisee, Lila

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

514 44, 4242771, 424 9321, 4352402, 4353201, A01N 4304, A01N 6300, A61K 3900, C12N 1500

Patent

active

058690352

ABSTRACT:
The invention discloses methods and compositions for killing tumor cells in animals. Through transfer techniques, cancer cells are engineered to express an epitope which is targeted by natural antibodies causing complement destruction of transformed tumor cells that is typically associated with hyperacute xenograft rejection.

REFERENCES:
patent: 5560911 (1996-10-01), Koren et al.
patent: 5562904 (1996-10-01), Rother et al.
Kistner et al Proc. Natl. Acad. Sci. (1996) 93(20), pp. 10933-10938.
Takeuchi, Y, Dec. 1994, Type C Retrovirus Inactivation by Human Complement is Determined by Both the Viral Genome and the Producer Cell, J. of Virology, 68(12)8001-8007.
Squinto, S., 1995, Injectable Retroviral Particles for Human Gene Therapy, Advanced Drug Delivery Reviews 17 (1995) 213-226.
Rother, R., Oct. 1994, Expression of Recombinant Transmembrane CD59 in Paroxysmal Nocturnal Hemoglobinuria B Cells Confers Resistance to Human Complement, Blood, 85(8) 2604-2611.
Rother, R., Feb. 1994, Inhibition of Complement-Mediated Cytolysis by the Terminal Complement Inhibitor of Herpesvirus Saimiri, J. of Virology, 68(2) 730-737.
Rother, R., Nov. 1995, A Novel Mechanism of Retrovirus Inactivation in Human Serum Mediated by Anti-.alpha.-Galactosyl Natural Antibody, J. of Experimental Medicine, 182(5) 1345-1355.
Galili, U., 1993, Evolution and Pathophysiology of the Human Natural Anti-.alpha.-Galactosyl IgG (Anti-Gal) Antibody, Springer Semin Immunopathol 15:155-171.
Rother, R., Apr. 1995, Protection of Retroviral Vector Particles in Human Blood Through Complement Inhibition, Human Gene Therapy 6:429-435, Mary Ann Liebert, Inc., Publishers.
Galili, Uri, Aug. 1985, Human Natural Anti-.alpha.-Galactosyl IgG: II. The Specific Recognition of .alpha.(1.fwdarw.3)-linked Galactose Residues, J. Exp. Med. 162:573-582, The Rockefeller University Press.
Rollins, S., Mar. 1996, Retroviral Vector Producer Cell Killing in Human Serum is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response, Human Gene Therapy 7:619-626, Mary Ann Liebert, Inc., Publishers.
Parker, W., Aug. 1996, Transplantation of Discordant Xenografts: A Challenge Revisited, Immunology Today Review; 17(8) 373-378.
Widner, H.ang.kan, Jul. 1988, Immunological Aspects of Grafting in the Mammalian Central Nervous System. A Review and Speculative Synthesis, Brain Research Reviews 13:287-324.
Neethling, F., Mar. 1994, Protection of Pig Kidney (PK15) Cells from the Cytotoxic Effect of Anti-Pig Antibodies by a-Galactosyl Oligosaccharides, Transplantation, 57(6) 959-963.
Weisman, H., Recombinant Soluble CR1 Suppressed Complement Activation, Inflammation, and Necrosis Associated with Reperfusion of Ischemic Myocardium, Transactions of the Association of American Physicians, V. 103:64-72, at Washington, D.C. May 4-7, 1990.
Galili, U., (1988) The Natural Anti-Gal Antibody, the B-Like Antigen, and Human Red Cell Aging, Blood Cells 14:205-220 (Article); 14:221-224 (Commentary); 14:225-228 (Reply to Commentary).
Almeida, I, Apr. 1991), Complement-Mediated Lysis of Trypanosoma Cruzi Trypomastigotes by Human Anti-a-Galactosyl Antibodies, J. of Immunology, 147(7) 2394-2400.
Hamadeh, R., Human Natural Anti-Gal IgG Regulates Alternative Complement Pathway Activation on Bacterial Surfaces, Apr. 1992, J. of Clinical Investigation, Inc. 89:1223-1235.
Galili, U., Interaction Between Human Natural Anti-a-Galactosyl Immunoglobulin G and Bacteria of the Human Flora, Jul. 1988, Infection and Immunity, vol. 56:1730-1737.
Cosset, F., Dec. 1995, High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum, J. of Virology, 69(12) 7430-7436.
Galili, U., 1995, .alpha.-Galactosyl (Gal.alpha.1-3Gal.beta.1-4GLCNAC-R) Epitopes on Human Cells: Synthesis of the Epitope on Human Red Cells by Recombinant Primate .alpha.1,3Galactosyltransferase Expressed in E.Coli, Glycobiology, 5(8):775-782.
Weisman, H., Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis, Science, 249:146-150.
Weiler, J., May 1992, Heparin and Modified Heparin Inhibit Complement Activation In Vivo, J. of Immunology, 148(10) 3210-3215.
Gorelik, E., Sep. 1995, Alterations of Cell Surface Carbohydrates and Inhibition of Metastatic Property of Murine Melanomas by a1,3 Galactosyltransferase Gene Transfection, Cancer Research, 55:4168-4173.
Joziasse, D., Aug. 1989, Bovine .alpha.1.fwdarw.3-Galactosyltransferase: Isolation and Characterization of a cDNA Clone: Identification of Homologous Sequences in Human Genomic DNA, J. of Biological Chemistry, 264(24)14290-14297.
Russell, D., May 1995, The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines, Human Gene Therapy 6:635-641, Mary Ann Liebert, Inc., Publishers.
Paulus, W., Jan. 1996, Self-Contained, Tetracycline-Regulated Retroviral Vector System for Gene Delivery to Mammalian Cells, J. of Virology, 70(1) 62-67.
Galili, U., Nov. 1988, Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of a-Galactosyl Epitopes on Nucleated Cells, J. of Biological Chemistry, 268(33) 17755-17762.
Larsen, R., Apr. 1990, Frameshift and Nonsense Mutations in a Human Genomic Sequence Homologous to a Murine UDP-Gal:.beta.-D-Gal(1,4)-D-GlcNAc .alpha. (1,3)-Galactosyltransferase cDNA, J. of Biological Chemistry, 265(12) 7055-7061.
Somerville, C., 1993, Future Directions in Transplantation:Xenotransplantation, Kidney International, vol. 44, Suppl. 42(1993) S-112-S121.
Leventhal, J., Prolongation of Cardiac Xenograft Survival by Depletion of Complement, Transplantation, 55(4) 857-866.
Pruitt, S., Feb. 1994, The Effect of Soluble Complement Receptor Type 1 on Hyperacute Rejection of Procine Xenografts, Transplantation 57(3) 363-370.
Galili, U., Nov. 1984, A Unique Natural Human IgG Antibody with Anti-.alpha.-Galactosyl Specificity, J. Exp. Med., 160:1519-1531, The Rockefeller University Press.
Galili, U., Aug. 1991, Gene Sequences Suggest Inactivation of a-1,3-Galactosyltransferase in Catarrhines After the Divergence of Apes from Monkeys, Proc. Natl. Acad. Sci. USA, 88:7401-7404.

Affiliated with

Also associated with

Rating

Methods and compositions for inducing complement destruction of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for inducing complement destruction of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inducing complement destruction of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1946610